Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Marinus Pharma CS (MRNS)

Marinus Pharma CS (MRNS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.5500 +0.0005 (+0.09%) 02/10/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.5500 unch (unch) -
Quote Overview for Mon, Feb 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.5489
Day High
0.5500
Open 0.5500
Previous Close 0.5495 0.5495
Volume 1,102,700 1,102,700
Avg Vol 1,233,208 1,233,208
Stochastic %K 96.44% 96.44%
Weighted Alpha -40.09 -40.09
5-Day Change +0.0025 (+0.46%) +0.0025 (+0.46%)
52-Week Range 0.2202 - 10.5000 0.2202 - 10.5000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,370
  • Shares Outstanding, K 55,218
  • Annual Sales, $ 30,990 K
  • Annual Income, $ -141,410 K
  • EBIT $ -125 M
  • EBITDA $ -124 M
  • 60-Month Beta 1.03
  • Price/Sales 1.00
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.44
  • Most Recent Earnings $-0.42 on 11/12/24
  • Next Earnings Date 03/04/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.29
  • Number of Estimates 5
  • High Estimate -0.19
  • Low Estimate -0.37
  • Prior Year -0.74
  • Growth Rate Est. (year over year) +60.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5300 +3.60%
on 01/21/25
Period Open: 0.5370
0.5560 -1.24%
on 01/13/25
+0.0121 (+2.25%)
since 01/10/25
3-Month
0.2202 +149.36%
on 12/23/24
Period Open: 0.3347
0.5560 -1.24%
on 01/13/25
+0.2144 (+64.06%)
since 11/11/24
52-Week
0.2202 +149.36%
on 12/23/24
Period Open: 10.1000
10.5000 -94.77%
on 03/01/24
-9.5509 (-94.56%)
since 02/09/24

Most Recent Stories

More News
Marinus Pharmaceuticals: Q3 Earnings Snapshot

Marinus Pharmaceuticals: Q3 Earnings Snapshot

MRNS : 0.5500 (+0.09%)
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity

Check out these three micro-cap stocks that show big-time potential upside, but also pose face large obstacles to achieving success.

IWC : 115.26 (-1.63%)
LODE : 2.40 (-7.69%)
AMPX : 3.06 (-7.27%)
SPY : 568.59 (-1.19%)
MRNS : 0.5500 (+0.09%)
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?

Marinus is an under $2 biotech stock with Wall Street analysts price targets ranging from $2 to $13. Its upcoming trial results have big implications.

MRNS : 0.5500 (+0.09%)
Marinus Pharmaceuticals: Q2 Earnings Snapshot

Marinus Pharmaceuticals: Q2 Earnings Snapshot

MRNS : 0.5500 (+0.09%)
Marinus Pharmaceuticals: Q1 Earnings Snapshot

Marinus Pharmaceuticals: Q1 Earnings Snapshot

MRNS : 0.5500 (+0.09%)
Marinus Pharmaceuticals: Q4 Earnings Snapshot

Marinus Pharmaceuticals: Q4 Earnings Snapshot

MRNS : 0.5500 (+0.09%)
Marinus Pharmaceuticals: Q3 Earnings Snapshot

Marinus Pharmaceuticals: Q3 Earnings Snapshot

MRNS : 0.5500 (+0.09%)
Marinus Pharmaceuticals: Q2 Earnings Snapshot

Marinus Pharmaceuticals: Q2 Earnings Snapshot

MRNS : 0.5500 (+0.09%)
Marinus Pharmaceuticals: Q1 Earnings Snapshot

Marinus Pharmaceuticals: Q1 Earnings Snapshot

MRNS : 0.5500 (+0.09%)
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present...

MRNS : 0.5500 (+0.09%)

Business Summary

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical...

See More

Key Turning Points

3rd Resistance Point 0.5515
2nd Resistance Point 0.5507
1st Resistance Point 0.5504
Last Price 0.5500
1st Support Level 0.5493
2nd Support Level 0.5485
3rd Support Level 0.5482

See More

52-Week High 10.5000
Fibonacci 61.8% 6.5731
Fibonacci 50% 5.3601
Fibonacci 38.2% 4.1471
Last Price 0.5500
52-Week Low 0.2202

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies